Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aptose Biosciences Initiates Enrollment for TUS+VEN+AZA Triplet Therapy in Newly Diagnosed AML Patients Quiver Quantitative, Inc. - Mon Dec 9, 9:22PM CST

Aptose Biosciences announces enrollment for TUS+VEN+AZA trial, targeting newly diagnosed AML patients with promising safety and efficacy.Quiver AI SummaryAptose Biosciences Inc. has announced the enrollment...

APTO : 0.1839 (-2.85%)
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML GlobeNewswire - Mon Dec 9, 11:00AM CST

APTO : 0.1839 (-2.85%)
APS.TO : 0.2600 (-3.70%)
Aptose Biosciences' Tuspetinib Selected for National Cancer Institute's myeloMATCH Trials Targeting AML and MDS Quiver Quantitative, Inc. - Tue Dec 3, 4:48PM CST

Tuspetinib is selected for the NCI's myeloMATCH trials to treat AML and MDS with targeted drug combinations.Quiver AI SummaryAptose Biosciences announced that its lead compound, tuspetinib, has been selected...

APTO : 0.1839 (-2.85%)
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials GlobeNewswire - Tue Dec 3, 6:30AM CST

APTO : 0.1839 (-2.85%)
APS.TO : 0.2600 (-3.70%)
Insider Purchase: Chair of $APTO (APTO) Buys 100,000 Shares Quiver Quantitative, Inc. - Wed Nov 27, 4:16AM CST

William G. Rice, the Chair of $APTO ($APTO), bought 100,000 shares of the company on 11-25-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

APTO : 0.1839 (-2.85%)
Aptose Biosciences Closes $8 Million Public Offering for Oncology Development Quiver Quantitative, Inc. - Tue Nov 26, 1:36AM CST

Aptose Biosciences closed an $8 million public offering, selling 40 million shares and 20 million warrants for funding.Quiver AI SummaryAptose Biosciences Inc. announced the successful completion of a...

APTO : 0.1839 (-2.85%)
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering GlobeNewswire - Mon Nov 25, 3:15PM CST

APTO : 0.1839 (-2.85%)
APS.TO : 0.2600 (-3.70%)
Aptose Biosciences Inc. Announces Pricing of Public Offering to Raise Approximately $8 Million Quiver Quantitative, Inc. - Fri Nov 22, 5:20PM CST

Aptose Biosciences announces pricing for a public offering of 40 million shares and 20 million warrants, aiming for $8 million in proceeds.Quiver AI SummaryAptose Biosciences Inc. has announced the pricing...

APTO : 0.1839 (-2.85%)
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering GlobeNewswire - Fri Nov 22, 7:00AM CST

APTO : 0.1839 (-2.85%)
APS.TO : 0.2600 (-3.70%)
Aptose Biosciences Initiates TUSCANY Study for Tuspetinib Combination Therapy in Newly Diagnosed Acute Myeloid Leukemia Patients Quiver Quantitative, Inc. - Wed Nov 20, 4:48PM CST

The TUSCANY study enrolls patients for a triplet therapy targeting newly diagnosed acute myeloid leukemia.Quiver AI SummaryAptose Biosciences Inc. has announced the launch of the TUSCANY study, which will...

APTO : 0.1839 (-2.85%)

Barchart Exclusives

These 2 Dividend Stocks Were Stars in November. Is It Too Late to Buy? Barchart - Wed Dec 11, 6:30PM CST
These high-yield dividend stocks have posted great returns in 2024 and could keep heating up in the new year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot